文献速递头颈外科

吸烟对经口机器人手术治疗口咽癌的影响:系统综述与荟萃分析

Effect of Smoking in Oropharyngeal Cancer Treated With TORS: Systematic Review and Meta-Analysis.
PubMed 文献 · Laryngoscope · 2026-05-08

该系统综述与荟萃分析纳入12项研究共2079例以HPV相关为主的口咽鳞癌患者,均接受经口机器人手术(TORS)。固定效应模型显示,有吸烟史者疾病复发风险比为1.4(95%CI 1.0-2.0),总生存风险比为2.7(95%CI 1.5-4.8),疾病特异性生存风险比为1.4(95%CI 0.4-4.6)。结论认为无复发生存和疾病特异性生存无显著差异,有吸烟史者总生存可能更差,但仅5项研究报告该结局。

要点

  • 有吸烟史者总生存风险比2.7(95%CI 1.5-4.8),提示预后更差。
  • 无复发生存和疾病特异性生存与吸烟史无显著差异。
  • 总生存分析仅基于5项研究,需更多研究验证。

核心结论

  • 在以HPV相关为主接受TORS治疗的口咽鳞癌人群中,有吸烟史与无吸烟史者的无复发生存和疾病特异性生存无显著差异。
  • 有吸烟史者总生存似乎更差,但仅5项研究报告该结局,需进一步研究明确吸烟的预后影响。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、CENTRAL和Scopus。
  • 纳入12项报告HPV相关口咽鳞癌接受TORS治疗并按吸烟史报告肿瘤学结局的研究,共2079例患者。

主要发现

  • 纳入患者中位年龄58.5岁,男性1808例(87.0%),HPV相关疾病1681例(80.9%)。
  • T分期以T2最多(831例,40.0%),T1为764例(36.7%);N分期N2为854例(41.1%),N1为544例(26.2%),N0为307例(14.8%)。
  • 有吸烟史931例(44.8%),无吸烟史1045例(50.3%),中位随访33.7个月。
  • 固定效应模型荟萃分析:疾病复发风险比1.4(95%CI 1.0-2.0),总生存风险比2.7(95%CI 1.5-4.8),疾病特异性生存风险比1.4(95%CI 0.4-4.6)。

关键数值与推荐

  • 疾病复发风险比1.4(95%CI 1.0-2.0)。
  • 总生存风险比2.7(95%CI 1.5-4.8)。
  • 疾病特异性生存风险比1.4(95%CI 0.4-4.6)。

临床怎么用

  • 对有吸烟史的口咽癌TORS术后患者,应关注总生存可能更差的风险,加强随访与综合管理。
  • counselling戒烟仍有意义,但本研究未提供戒烟干预对结局影响的证据。

局限性

  • 总生存分析仅基于5项研究,证据有限。
  • 纳入研究为观察性设计,可能存在混杂偏倚。
  • 部分患者HPV状态未明确(HPV相关80.9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While smoking has been implicated as a risk factor for recurrence in HPV-associated oropharyngeal squamous cell cancer (OPSCC) treated with definitive chemoradiation, its prognostic impact on surgically treated OPSCC is less clear. DATA SOURCES: MEDLINE, Embase, CENTRAL, and Scopus. REVIEW METHODS: Articles describing patients with HPV-associated OPSCC treated with transoral robotic surgery (TORS), which reported oncologic outcomes by smoking history, were included. RESULTS: 2079 patients were included across 12 studies. Median age was 58.5 years, and 1808 (87.0%) were male. HPV-associated disease was reported in 1681 (80.9%) patients. T stage was most commonly T2 in 831 (40.0%) and T1 in 764 (36.7%). N stage was N2 in 854 (41.1%), N1 in 544 (26.2%), and N0 in 307 (14.8%). 931 (44.8%) were considered individuals with a smoking history, while 1045 (50.3%) were considered without a smoking history. Median follow up was 33.7 months. Meta-analysis using a fixed effects model demonstrated an overall hazard ratio of 1.4 (95% confidence interval 1.0-2.0) for disease recurrence, 2.7 (95% confidence interval 1.5-4.8) for overall survival, and 1.4 (95% confidence interval 0.4-4.6) for disease specific survival. CONCLUSIONS: In this population of predominantly HPV-associated OPSCC treated with TORS, meta-analysis demonstrated no significant difference in recurrence-free survival or disease-specific survival between individuals with and without a smoking history. Individuals with a smoking history appeared to have worse overall survival, although only five studies reported on this outcome. Further research is required to clarify the prognostic influence of smoking on OPSCC treated with TORS.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Tong JY, Amin N, Cruess C, et al. Effect of Smoking in Oropharyngeal Cancer Treated With TORS: Systematic Review and Meta-Analysis. Laryngoscope. 2026. PMID: 42103481. doi:10.1002/lary.70605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。